secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alaunos Therapeutics, Inc. (TCRT)
CIK:        0001107421
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001193125-23-212358
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alaunos Therapeutics winds down TCR-T trial, cuts workforce 60%, explores strategic alternatives
--------------------------------------------------------------------------------

- Q2 2023 net loss $8.8M ($0.04 per share); cash $18.3M, expected to fund ops into Q4 2023.
- Wind-down of TCR-T Library Phase 1/2 trial; 83% disease control rate in 6 evaluable patients.
- Workforce reduction of ~60%; retains key hunTR platform R&D capabilities.
- Engaged Cantor Fitzgerald to explore strategic alternatives including sale, merger, or partnerships.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1107421/000119312523212358/0001193125-23-212358-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1107421/000119312523212358/d467190d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-212358

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer